Clinical Trials Logo

Cord Blood Transplant Recipient clinical trials

View clinical trials related to Cord Blood Transplant Recipient.

Filter by:
  • None
  • Page 1

NCT ID: NCT03941769 Completed - Clinical trials for Acute Myeloid Leukemia

2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II

Start date: September 29, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies side effects and best dose of recombinant interleukin-7 in promoting immune cell recovery in patients with acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, or myeloproliferative disease after a haploidentical or cord blood stem cell transplant. A haploidentical transplant is a transplant that uses stem cells from a donor that is partially (at least 50%) matched to the patient. Umbilical cord blood is a source of blood-forming cells that can be used for transplant, also known as a graft. However, there is a small number of blood-forming cells available in the transplant, which may delay the "take" of the graft in the recipient. Recombinant interleukin-7 may affect the "take" of the graft and the recovery of certain blood cells related to the immune system (called T-cells, natural killer cells, and B cells) in patients who have had a haploidentical or cord blood stem cell transplant.

NCT ID: NCT01927731 Completed - Clinical trials for Hematopoietic Cell Transplantation Recipient

Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

Start date: October 14, 2013
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well eltrombopag olamine works in increasing platelet counts in patients undergoing transplant. Eltrombopag olamine may help platelet counts and the immune system recover from blood or bone marrow transplant.